Tumor Chemosensitivity Assays

Aetna excludes tumor chemosensitivity assays (e.g., ChemoFx, DiSC, Cytoprint, HTCA, MTT, MiCK/CorrectChemo, NexGen Cancer Cytotoxicity, 3D Predict Glioma, Reverse Phase Protein Array and specified CPT/HCPCS/test codes) as experimental and investigational because there is insufficient reliable evidence that they change management or improve clinical outcomes. Use is not recommended outside clinical trials per ASCO/NCCN guidance and no prospective trials have shown survival benefit.

"Explicit technologies/procedures designated investigational (no covered indications listed): ChemoFx assay; differential staining cytotoxicity (DiSC) assay; fluorescence (Cytoprint) assay; human tu..."

Sign up to see full coverage criteria, indications, and limitations.